Propecia Generic For Male Pattern Baldness

The drug propecia generic was originally intended for treating prostate enlargement or benign prostatic hyperplasia. When its branded name Proscar was released in the market, it was noticed that men who were suffering from androgenic alopecia were also being treated by the drug.  It was then that the manufacturer took notice and created some clinical studies and found out that Proscar, which came at 5mg, which at lowered dosage, particularly 1mg, could help fight androgenic alopecia.  Several years later, the brand Propecia, an offshoot of the drug Proscar was approved by the Food and Drug Administration as a treatment for androgenic alopecia.

Who is propecia generic intended for?

Propecia generic is meant for men suffering from male pattern baldness and want to stop the progression of their hair loss.  Signs of male pattern baldness would be the thinning of hair on the front, the receding of hairline on the temples, and the formation of a bald spot on the crown.  In due time, this type of baldness will let you end up bald from top to front with a rim of hair at the sides and back.  propecia generic is effective against this type of hair loss because it is able to treat it at the root of the cause – the formation of the hormone dihydrotestosterone (DHT).  Basically, this hair loss treatment prevents your hair loss from getting any worse.  If your hair loss is due to androgenic alopecia, then this is the medication for you.  Consult your doctor to know what type of hair loss you are having. Read more…

New fibrage-statin combos work their way through the system


The FDA is looking for more data to support a new US drug application for a product called Certriad which combines two cholesterol meds -- Abbott's TriLipix and AstraZeneca's Crestor.

TriLipix is a class of drugs called fibrages that boost "good" cholesterol and reduce triglycerides, a fat found in the blood stream, and "bad" cholesterol. Crestor is a statin that raises "good" HDL cholesterol while reducing "bad" HDL cholesterol.

The new product is intended to treat dyslipikemia, which results from elevated cholesterol and triglycerides. More than 100 million Americans suffer from the disorder says The American Heart Association.

The companies will continue to work with the FDA.

Studies on the effectiveness of statins in the prevention of cardiovascular disease are ongoing. One of many was reported in Journal Watch Cardiology last August by Dr Harlan Krumholz It results came from of an analysis of 10 trials with over 70,000 subjects over an average of 4 years, mean age 63, mean baseline LDL level 140, 2/3rds were male., ¼ of those had diabetes. Mortality was 5.7% in the control groups and 5.1% in the statin group. Go to http://bit.ly/bqbdnc for more.

The study concluded that statins can reduce the risk of cardiovascular events in those without cardiovascular disease.

Lowering heart attack and stroke the Mayan/Aztec way

On a recent visit to Santa Fe, New Mexico, was taken to a café that serves nothing but hot chocolate drinks. Most of them are derived from original recipes from South and Central America. The most popular beverage on the menu was the Mexican Full Spice Elixir. The only sweetener used is algave, and that extremely sparingly. Delicious and unusual.

The Kakawa Café may be onto something. Fully 39 % of the 20,000 participants in a just published German study who ate six grams (the equivalent of a single square from a chocolate bar) lowered their risk of heart attack and stroke. Researchers believe it's flavonols in chocolate widen blood vessels leading to a drop in blood pressure.

Though the study makes no dietary recommendations, a small square of dark chocolate makes a good replacement for snacks high in sugar, salt and fat, says Brian Buijsse, the lead author.

The enphasis is on the "small" size of the amount ingested. Eating large amounts of chocolate would result in weight gain that would be far worse than any benefits from the extra flavonols. A 100 grams of chocolate contains 500 calories.

The study was published today in the European Heart Journal